Search details
1.
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
JAMA
; 320(20): 2108-2121, 2018 11 27.
Article
in English
| MEDLINE | ID: mdl-30480729
2.
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the T-Type Calcium Channel Blocker ABT-639 in an Intradermal Capsaicin Experimental Pain Model in Healthy Adults.
Pain Med
; 17(3): 551-560, 2016 03.
Article
in English
| MEDLINE | ID: mdl-26814294
3.
Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials.
Br J Clin Pharmacol
; 75(4): 1029-40, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-22966986
4.
An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.
Br J Clin Pharmacol
; 75(2): 404-14, 2013 Feb.
Article
in English
| MEDLINE | ID: mdl-22775239
5.
Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema.
J Allergy Clin Immunol Pract
; 5(5): 1402-1409.e3, 2017.
Article
in English
| MEDLINE | ID: mdl-28552382
6.
Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
J Allergy Clin Immunol Pract
; 5(6): 1671-1678.e2, 2017.
Article
in English
| MEDLINE | ID: mdl-28601641
7.
Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial.
Pain
; 156(11): 2175-2183, 2015 Nov.
Article
in English
| MEDLINE | ID: mdl-26035253
8.
Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.
AAPS J
; 17(2): 416-26, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25567367
9.
A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain.
Pain
; 156(10): 2013-2020, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26067585
10.
Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials.
J Clin Pharmacol
; 52(7): 1028-41, 2012 Jul.
Article
in English
| MEDLINE | ID: mdl-21566201
11.
A Phase 1 Study to Evaluate the Bioavailability and Food Effect of 2 Solid-Dispersion Formulations of the TRPV1 Antagonist ABT-102, Relative to the Oral Solution Formulation, in Healthy Human Volunteers.
Clin Pharmacol Drug Dev
; 1(1): 24-31, 2012 Jan.
Article
in English
| MEDLINE | ID: mdl-27206143
12.
Efficacy and safety of the α4ß2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain.
Pain
; 153(4): 862-868, 2012 Apr.
Article
in English
| MEDLINE | ID: mdl-22386472
13.
Reply.
J Allergy Clin Immunol Pract
; 5(6): 1803-1804, 2017.
Article
in English
| MEDLINE | ID: mdl-29122164
14.
Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial.
Pain
; 152(5): 1192-1200, 2011 May.
Article
in English
| MEDLINE | ID: mdl-21377273
15.
Erratum to: population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.
AAPS J
; 17(2): 481-92, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-25676842
16.
A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain.
Pain
; 146(3): 245-252, 2009 Dec.
Article
in English
| MEDLINE | ID: mdl-19632048
Results
1 -
16
de 16
1
Next >
>>